Thrombocytopenia in lupus: Baseline C3 as an independent risk factor for relapse [1]

Annals of the Rheumatic Diseases

Volumn 66, Issue 1, 2007, Pages 130-131

  Ziakas, P D ^a   Poulou, L S ^a   Giannouli, S ^a   Tzioufas, A G ^a   Voulgarelis, M ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CARDIOLIPIN ANTIBODY; COMPLEMENT COMPONENT C3; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ARTHRITIS; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; COMORBIDITY; COMPLEMENT ACTIVATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; KIDNEY DISEASE; LETTER; PRIORITY JOURNAL; RASH; RELAPSE; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

COMPLEMENT C3; HUMANS; LUPUS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOCYTOPENIA;

EID: 33846001960     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2006.059758     Document Type: Letter

References (9)

1. Arnal C, Piette JC, Leone J, Taillan B, Hachulla E, Roudot-Thoraval F, et al. Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases. J Rheumatol 2002;29:75-83.
2. Boumpas DT, Barez S, Klippel JH, Balow JE. Intermittent cyclophosphamide for the treatment of autoimmune thrombocytopenia in systemic lupus erythematosus. Ann Intern Med 1990;112:674-7.
3. Avina-Zubieto JA, Galindo-Rodriguez G, Robledo I, Vela-Ojeda J, Vadillo-Buenfil M, Rosas-Cabral A, et al. Long-term effectiveness of danazol corticosteroids and cytotoxic drugs in the treatment of hematologic manifestations of systemic lupus erythematosus. Lupus 2003;12:52-7.
4. Kneitz C, Wilhelm M, Tony HP. Effective B cell depletion with rituximab in the treatment of autoimmune diseases. Immunobiology 2002;206:519-27.
5. Vasoo S, Thumboo J, Fong KY. Refractory immune thrombocytopenia in systemic lupus erythematosus: response to mycophenolate mofetil. Lupus 2003;12:630-2.
6. You YN, Tefferi A, Nagorney DM. Outcome of splenectomy for thrombocytopenia associated with systemic lupus erythematosus. Ann Surg 2004;240:286-92.
7. Ziakas PD, Giannouli S, Zintzara E, Tzioufas AG, Voulgarelis M. Lupus thrombocytopenia: clinical implications and prognostic significance. Ann Rheum Dis 2005;64:1366-9.
8. Mosca M, Bencivelli W, Vitali C, Carrai P, Neri R, Bombardieri S. The validity of the ECLAM index for the retrospective evaluation of disease activity in systemic lupus erythematosus. Lupus 2000;9:445-50.
9. Ho A, Barr SG, Magder LS, Petri M. A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus. Arthritis Rheum 2001;44:2350-7.